- Protocol No
- P24-903
EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)
- Start date
- 21/03/2025
- Medical condition
- 3L+DLBCL/FL
Clinical Trials
- Protocol No
- 64407564MMY4001
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma (MoMMent)
- Start date
- 17/03/2025
- End date
- Recruiting
- Medical condition
- R/R MM
- EudraCT / EU CT No
- 2024-515279-37-00
- Protocol No
- CA088-1007
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Start date
- 12/03/2025
- End date
- Recruiting
- Medical condition
- Relapsed or refractory, lenalidomide-exposed multiple myeloma
- Protocol No
- 160/27022025
Digital Support for Multiple Myeloma Quality of Life (DigiMyQoL)
- Start date
- 27/02/2025
- End date
- 03/2028
- Medical condition
- Multiple myeloma; quality of life
- EudraCT / EU CT No
- 2024-512147-23-00
- Protocol No
- M24-287
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects with CLL
- Start date
- 07/02/2025
- Medical condition
- Untreated CLL
- EudraCT / EU CT No
- 2021-003313-18
- Protocol No
- MK2140-003
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003)
- Start date
- 17/01/2025
- Medical condition
- R/R DLBCL
- EudraCT / EU CT No
- 2024-510805-27-00
- Protocol No
- NN7535-7822
An open-label, multi-centre, rollover study to characterise long-term safety and efficasy of Etavopivat in adults, adolescents and children who have sickle cell disease or thalassaimia and have completed a treatment period in an etavopivat study
- Start date
- 09/01/2025
- End date
- 11/2029
- Medical condition
- sickle cell
- EudraCT / EU CT No
- 2023-509175-16
- Protocol No
- NN7535-7807
A global, Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.
- Start date
- 2025
- End date
- 2029
- Medical condition
- Adolescent and adult patients with sickle cell disease
- EudraCT / EU CT No
- 2024-518645-17
- Protocol No
- EFC17872
A multicenter, randomized, double-blind, placebo-controlled, parallel-group, sequential group, 52-week Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle cell disease.
- Start date
- 2025
- End date
- Recruiting
- Medical condition
- Patients aged 10 to 65 years with sickle cell disease
- EudraCT / EU CT No
- 2024-511309-47-00
- Protocol No
- XPORT-MF-044
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor (JAKi)-naïve Myelofibrosis and Moderate Thrombocytopenia
- Start date
- 10/12/2024
- End date
- End of 2027
- Medical condition
- MF